BIOLOGICAL INTERACTIONS OF EXTRACELLULAR VESICLES CONTRIBUTING TO METASTASIS OF BREAST CANCER AND OSTEOSARCOMA
Raluca Ghebosu, PhD Candidate
Australian Institute for Bioengineering and Nanotechnology
University of Queensland, Brisbane, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Queensland, Australia | October 2024
Raluca Ghebosu graduated from the University of Queensland with a Bachelor of Arts/Bachelor of Science with majors in Japanese and Biomedical Science (2018-2021). She then completed her Bachelor of Science (Honours) with the School of Biomedical Sciences at the University of Queensland in 2022, before pursuing a PhD with A/Prof. Joy Wolfram at the Australian Institute for Bioengineering and Nanotechnology.
Raluca is currently exploring the complex biological interactions of extracellular vesicles, with the goal of understanding how they can contribute to the metastasis of breast cancer and osteosarcoma. She will do this by uncovering how extracellular vesicles from breast cancer and osteosarcoma cells allow the cancer cells to evade the immune system and avoid being detected by Natural Killer cells. By shedding light on the complex role of extracellular vesicles in cancer metastasis she hopes to revolutionise nanoparticle and cell-based cancer treatments.
Since beginning her PhD in 2023, Raluca has published two first author and two co-author manuscripts in high-ranking journals, including a first author paper in the premier journal of her field, Journal of Extracellular Vesicles (IF: 15.5), and has gained over 500 citations across her publications. She has presented her work to various audiences including scientists, clinicians and consumers and is a University of Queensland, 2024 3 Minute Thesis finalist. Raluca is also involved with the Wonder of Science Outreach program that promotes scientific inquiry and engagement to school-aged students across Queensland. Raluca hopes to continue being an advocate for STEM education and sharing her work with consumers and the broader scientific community
https://orcid.org/0000-0001-8839-3512
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Paediatric obesity prevention, nutrition and dietetics
Leveraging a systems-based and collaborative approach, Dr Littlewood over the past 25 years has driven research and data outcomes in the area of health and wellbeing. Dr Littlewood leads a dedicated team focused on making healthy happen for all Queenslanders, with a particular focus on improving health outcomes for the next generation.
-
Dr Kelly-Anne Masterman
RESEARCH IN NEEDLE-FREE VACCINE DELIVERY SYSTEM
@ VAXXAS, BRISBANE, QUEENSLAND, AUSTRALIA
